Catalyst Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Nassim Usman

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	24.9%
CEO tenure	8.3yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	8.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nassim Usman's remuneration changed compared to Catalyst Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	US$7m
Dec 31 2022	US$2m	US$595k	-US$8m
Sep 30 2022	n/a	n/a	US$12m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$1m	US$595k	-US$88m
Sep 30 2021	n/a	n/a	-US$87m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$1m	US$574k	-US$56m
Sep 30 2020	n/a	n/a	-US$51m
Jun 30 2020	n/a	n/a	-US$48m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$1m	US$525k	-US$55m
Sep 30 2019	n/a	n/a	-US$52m
Jun 30 2019	n/a	n/a	-US$47m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$2m	US$481k	-US$30m
Sep 30 2018	n/a	n/a	-US$25m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$2m	US$464k	-US$26m
Sep 30 2017	n/a	n/a	-US$24m
Jun 30 2017	n/a	n/a	-US$22m
Mar 31 2017	n/a	n/a	-US$17m
Dec 31 2016	US$570k	US$453k	-US$17m

Compensation vs Market: Nassim's total compensation ($USD2.39M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Nassim's compensation has increased whilst the company is unprofitable.

CEO

Nassim Usman (63 yo)

8.3yrs

Tenure

US$2,392,782

Compensation

Dr. Nassim Usman, Ph.D. serves as a Venture Partner at Morgenthaler Ventures. Dr. Usman is a part of the life sciences team. He joined Morgenthaler as an Entrepreneur-in-Residence in 2005 and has also serv...

Board Members

Name	Position	Tenure	Compensation	Ownership
Nassim Usman	President	8.3yrs	US$2.39m	no data
Augustine Lawlor	Independent Chairman of the Board	17.8yrs	US$91.00k	no data
James Wells	Member of Scientific Advisory Board	no data	no data	no data
Shaun Coughlin	Member of Scientific Advisory Board	no data	no data	no data
Edwin Madison	Member of Scientific Advisory Board	7.2yrs	US$695.83k	no data
Thomas Eastling	Independent Director	less than a year	no data	no data
Ying Luo	Independent Director	less than a year	no data	no data
David Ginsburg	Member of Scientific Advisory Board	14.7yrs	no data	no data
Robert Fletterick	Member of Scientific Advisory Board	14.7yrs	no data	no data
Guy Salvesen	Member of Scientific Advisory Board	14.7yrs	no data	no data
Andrea Hunt	Independent Director	6.1yrs	US$50.00k	0.074% $ 13.6k

8.3yrs

Average Tenure

67yo

Average Age

Experienced Board: HGF2's board of directors are considered experienced (8.3 years average tenure).

Catalyst Biosciences Management

Management criteria checks 1/4

Key information

Recent management updates

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Insufficient new directors

Insider recently sold €289k worth of stock

Insider recently sold €513k worth of stock

Insider recently bought €891k worth of stock

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Recent updates

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings released: US$0.26 loss per share (vs US$2.87 loss in FY 2021)

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Insufficient new directors

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insider recently sold €289k worth of stock

Insider recently sold €513k worth of stock

Inaugural dividend of US$1.43 per share

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Catalyst Biosciences, Inc. Announces Dismissal of Jds1 Litigation

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

Forecast to breakeven in 2022

JEC II Associates, LLC Reaches an Agreement Catalyst Biosciences

JDS1 LLC Issues an Investor Presentation to Shareholders of Catalyst Biosciences Inc

JDS1, LLC Provides Information to the Shareholders

JEC II Associates Engages in Discussions with Catalyst Biosciences

Insider recently bought €891k worth of stock

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

JDS1 Files a Complaint against Catalyst Biosciences

JDS1 Provides Information to Shareholders of Catalyst Biosciences

Full year 2021 earnings released: US$2.87 loss per share (vs US$2.93 loss in FY 2020)

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian Singer Sends Letter to Catalyst Biosciences

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.96 loss in 2Q 2020)

Catalyst Biosciences Announces First Patient Screened for CFI Deficiency in Its CB 4332 Screening and Natural History of Disease Studies

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from Russell 3000E Value Index

Catalyst Biosciences, Inc. Announces Initiation of Dosing in the Company's Phase 1/2 Study (MAA-202) of Marzeptacog Alfa

Catalyst Biosciences Announces the Dosing of the First Patient in the Crimson 1 Study, the Company's Phase 3 Registration Trial (Maa-304 - Crimson 1)

Revenue beats expectations

New 90-day high: €6.00

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

New 90-day high: €5.50

Catalyst Biosciences, Inc. Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

New 90-day high: €5.40

New 90-day low: €3.70

New 90-day low - €4.18

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age